Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advance melanoma. Recruiting Principal Investigator Sasha SmiljanicBody Locations and Systems MelanomaArea VancouverAge 18 and above
A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis…The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.Recruiting Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 6-17
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe…The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)The purpose of this study is to assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With PsoriasisThe purpose of this study is to understand the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in a psoriasis study involving BMS-986165. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo SubjectsThe purpose of this study is to assess the safety and efficacy of PF-06651600 and PF-06700841 in participants with non-segmental vitiligo. Recruiting Principal Investigator Youwen ZhouBody Locations and Systems VitiligoArea VancouverAge 18-65
The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury (RE-ENERGIZE)The purpose of this study is to test the following hypotheses:Recruiting Principal Investigator William HendersonBody Locations and Systems Skin ConditionsArea VancouverAge 18 and above
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis (DETERMINE)The purpose of this study is to evaluate the efficacy and safety of lenabasum for the treatment of dermatomyositis. Recruiting Principal Investigator Jan P. DutzBody Locations and Systems Skin Conditions, MyositisArea VancouverAge 18 and above
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18-70
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older…The purpose of this study is to learn about the long-term safety and effectiveness of the study drug, PF-04965842 in participants who previously participated in PF-04965842 AD Phase 3 trials. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis…The purpose of this study is to evaluate the efficacy and safety of two dosage strengths of PF-04965842 (100 mg and 200 mg taken orally once daily) relative to placebo over 12 weeks of study participation. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
Chronic Plaque Psoriasis (Ps) RegistryThe purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps). Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-99
Psoriasis Longitudinal Assessment and Registry (PSOLAR)The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together).Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-99
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III…This is an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis. Closed for Recruitment Principal Investigator Youwen ZhouBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in…This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis. Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18 and above
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis. Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-99
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in…The purpose of this study is to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 24, to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with Closed for Recruitment Principal Investigator Jan P. DutzBody Locations and Systems Psoriasis, Psoriatic ArthritisArea VancouverAge 18 and above
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisTo assess the safety and tolerability of multiple oral doses of BMS-986165 in subjects with moderate to severe psoriasis.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems PsoriasisArea VancouverAge 18-70
Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2The purpose of this study is to investigate the safety and effectiveness of daily post surgical scar management, using a moisture-balancing base product containing different amounts of a novel (NCE) antifibrogenic compound FS2, a natural metabolite of the kynurenine pathway. Closed for Recruitment Principal Investigator Anthony PappBody Locations and Systems ScarsArea VancouverAge 18-65
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity…The purpose of this study is a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and will include an assessment of 1 or 2 additional doses in two subgroClosed for Recruitment Principal Investigator Jan P. DutzBody Locations and Systems ShinglesArea VancouverAge 50 and above
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006…The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects >= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) anClosed for Recruitment Principal Investigator Jan P. DutzBody Locations and Systems ShinglesArea VancouverAge 50 and above
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in…The purpose of this study is to evaluate the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Closed for Recruitment Principal Investigator David ZlotyBody Locations and Systems Skin ConditionsArea VancouverAge 18 and above
Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic DermatitisThis is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18 and above
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3The purpose of this study is to demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Closed for Recruitment Principal Investigator Sunil KaliaBody Locations and Systems Dermatitis, EczemaArea VancouverAge 18 and above
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic…The purpose of this study is to evaluate the efficacy and safety of two dosage strengths of a new drug (PF-04965842) relative to placebo over 20 weeks of study participation. recruitment poster Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12 and above
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDThe purpose of this extension trial is to evaluate the long-term safety of tralokinumab in patients with atopic dermatitis. Closed for Recruitment Principal Investigator Sunil KaliaBody Locations and Systems DermatitisArea VancouverAge 18 and above
A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy. Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 12-75
Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutationClosed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems MelanomaArea VancouverAge 18 and above
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma. Closed for Recruitment Principal Investigator Sasha SmiljanicBody Locations and Systems MelanomaArea North VancouverAge 18 and above
